What Happens to Inventory When a Substance Is Scheduled

When a temporary scheduling order publishes, covered stock on your shelf stops being sellable that day. There is no sell-through window, no grandfather clause for goods already bought and paid for, and no compensation. If you are not a DEA registrant — and no registration permits retail sale of a Schedule I substance to the public — the obligation is to surrender the inventory, not to move it.

That is harsh, and much of the confident advice in this category says otherwise. Here is what the orders actually say, where the "30 days" myth comes from, and what a wholesale buyer should do now.

Quick Answer: The Timeline for Stock on Hand

Where the "Grace Period" Myth Comes From

Three separate things get compressed into one imagined runway.

The 30-day waiting period. Under 21 U.S.C. 811(h)(1), the DEA may not issue a temporary scheduling order until 30 days after the Notice of Intent publishes. The Notices in this action published on July 6, 2026, which is why the earliest possible effective date is on or after August 5, 2026. That 30 days is a constraint imposed on the agency. It expires before the order issues. It is not a compliance window for anyone holding product, and it is already over on the day the order lands.

FDA compliance dates. People reasonably expect a phase-in because that is how food labeling rules work. FDA rules routinely carry a compliance date months or years after publication. Scheduling orders do not. The notice says plainly that the order will take effect on the date it is published in the Federal Register, and will remain in effect for two years with a possible extension of one more.

The registrant paperwork allowances. Scheduling orders do contain 30-day allowances, and this is where the myth gets its foothold. Those allowances go to businesses that already hold a DEA registration, and they cover paperwork only: labeling and packaging updates, taking an initial inventory, and recordkeeping. If someone tells you "the DEA gives you 30 days to clear inventory," they have read a registrant paperwork provision and applied it to someone it never covered. A non-registrant retailer or distributor gets nothing.

The historical record is consistent: temporary scheduling orders spanning fifteen years — synthetic cathinones in 2011, nitazenes in 2022 and again in 2025 — all took effect on their publication date, none with a wind-down. For the underlying authority, see DEA temporary scheduling explained.

Notice of Intent Versus the Order Itself

One distinction saves a lot of confusion. What published on July 6 was a notice of intent. It announces scope and starts the clock, and it does not itself control anything. The document that carries the operative provisions — including the registration requirement and the disposal-of-stocks section — is the temporary scheduling order that follows.

So the deadline is real but the exact date is not fixed. "On or after August 5" is not "on August 5," and you will get no advance warning of which day the order publishes. Planning to the earliest possible date is the only sensible posture.

What the Order Says About Stock, in So Many Words

The modern order template is unusually direct. Three lines matter to anyone holding product:

• Retail sales of Schedule I controlled substances to the general public are not allowed under the Controlled Substances Act.
• Possession of any quantity of the covered substances, in a manner not authorized by the CSA, on or after the effective date is unlawful.
• Any person who does not desire or is unable to obtain a Schedule I registration must surrender all currently held quantities. The word is must, not may.

There is also no judicial off-ramp. Under 21 U.S.C. 811(h)(6), an order issued under that authority is not subject to judicial review, so the familiar strategy of filing for a restraining order to buy a few weeks does not exist here.

Registration Is Not an Escape Hatch

The first instinct of most owners is to ask whether they can simply register. The Schedule I registration categories are manufacturer, distributor, importer, exporter, researcher, analytical laboratory and instructional activities. Two features of that list end the conversation for a retail business.

First, a Schedule I distributor registration authorizes distribution to other registrants only. It never authorizes sale to a consumer. Second, Schedule I means no currently accepted medical use, so there is no prescription channel either. There is no lawful retail path for a Schedule I substance at any registration tier.

The template also states that an unregistered person who currently handles the substances must apply and may not continue to handle them as of the effective date unless the DEA has already approved that application. Applying is not approval. Note too how broadly these documents define "handle": manufacture, distribute, reverse distribute, import, export, research, instructional activities, chemical analysis, or simply possess.

How Surrender Actually Works

Two routes exist: a DEA-registered reverse distributor, a business that takes controlled substances out of commerce and documents their destruction, or direct coordination with your local DEA Diversion Control field office. Registrants record destruction on the agency's form; a non-registrant coordinates the transfer and keeps the paperwork.

Engage the field office before the effective date rather than after. Voluntary pre-effective-date contact with a clean, dated paper trail is the cheapest risk reduction available here. Keep every document: what you held, in what quantity, what you did with it, and when.

Nobody reimburses you. Not the DEA, not the FDA, and absent a specific contract term, not the brand whose product you bought. Because the agency treats a temporary order as something other than a "rule" for Administrative Procedure Act purposes, no inventory-loss analysis is performed at all. The loss is never quantified anywhere in the record.

Five Things People Try That Make It Worse

1. The clearance sale. "Last chance to stock up" is running across this market right now. It creates the in-transit problem described below, and it documents your own knowledge of the impending change — exactly the evidence prosecutors used in the synthetic cannabinoid cases.
2. Shipping it somewhere friendlier. After the effective date federal law applies in every state. There is no jurisdiction inside the United States where the stock becomes lawful again.
3. Returning it to the supplier. This is the one that catches careful people. After the effective date, shipping product back up the chain is itself a distribution of a Schedule I substance by an unregistered person.
4. Exporting it. Export of controlled substances carries its own registration requirement and its own offenses. It is not a way out.
5. Relabeling it "not for human consumption." This has been tried and litigated, and it lost. The government aggregates a seller's other content — product pages, social posts, affiliated sites — to establish intended use.

The Trap Nobody Plans For: Orders Across the Boundary

The offense attaches to distribution or possession on or after the effective date. It does not attach to the date the order was placed, or the date the customer paid. In a normal e-commerce operation that single fact creates a whole category of problems:

• Orders placed before the date but shipped after it.
• Backorders waiting on restock.
• Subscription and auto-ship renewals that fire on a schedule.
• Split shipments where one parcel goes out late.
• Dropship instructions passed to a brand partner who fulfills on their own timetable.
• Freight already in transit on the effective date.

The fix is unglamorous. Set a hard cutoff on order acceptance well before the earliest possible effective date, pause subscriptions on affected SKUs, and confirm that delivery is completed rather than merely dispatched before the boundary.

A Checklist for Wholesale Buyers

If you buy for a shop, a chain or a distribution operation, your work differs from a consumer's. In rough priority order:

1. Inventory by composition, not by brand name. Brands change formulations without changing packaging. What matters is what is in each article.
2. Get per-article certificates. The 7-OH schedule in FR Doc 2026-13580 is threshold-based — above 0.050% on a weight basis, or above 1.00 mg of 7-OH per article — so a certificate can genuinely establish that a SKU falls outside it. But FR Doc 2026-13581 covers mitragynine pseudoindoxyl, MGM-15 and MGM-16 with no threshold at all, and a panel that only looks for 7-OH cannot clear a product for compounds it never tested for. That gap is covered in what non-detect actually means.
3. Read your supplier agreements now. Find out what return, recall and credit rights you have before you need to exercise them.
4. Stop taking consignment or extended terms on borderline product. You do not want to be holding someone else's exposure on the effective date.
5. Move lawful stock while it is still lawful, with delivery completed before the boundary rather than dispatched near it.
6. Talk to your accountant about how a write-off of surrendered stock is treated. That is a real conversation with real numbers, better had in advance.

If you are setting up a supply relationship with us, our terms and the documentation we provide are on the wholesale page, and every certificate we hold for what we stock is on the COA page. We would rather a buyer audit our paperwork than take our word for anything.

What We Are Doing

We are a distributor and retailer of third-party brands. We do not manufacture, formulate or private-label anything, so our exposure runs through what we stock and what we say about it. The panels we hold report non-detect for 7-OH, mitragynine and several related leaf alkaloids; they do not test for mitragynine pseudoindoxyl, MGM-15, MGM-16 or corynoxine B, and we do not claim otherwise. For how brands built on 7-OH are handling the same deadline, see what happens to 7-OH brands. Our range is in the cat's claw collection.

Frequently Asked Questions

Can I sell through existing stock after the effective date?

No. Retail sale of a Schedule I substance to the general public is not permitted under the Controlled Substances Act, and temporary scheduling orders in this family have never included a sell-through provision.

What if I bought and paid for the inventory months before?

It makes no difference. The offense attaches to distribution and possession on or after the effective date, not to when you acquired the goods or what you paid for them.

Will anyone reimburse me for surrendered stock?

Not through any government mechanism. Whether your supplier will is purely a question of your contract — read those terms now.

Does this apply to everything in the category?

No. The action names specific compounds. Cat's claw (Uncaria tomentosa) is a different plant from kratom and is not named in it. Whether a given article is covered depends on that article's composition, which is a laboratory question.

How do I know whether my SKUs are affected?

Start with the certificate for each article and read the actual analyte list rather than the summary line. Our guide to reading a COA covers what to look for, including the difference between a compound reported as non-detect and a compound that was never on the panel at all.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Legality depends on the specific formulation and applicable state law — check the rules where you live. Nothing here is legal advice.